Literature DB >> 22996421

[Mistletoe extract for treatment of urological tumors].

H Suttmann1, M Saar, C H Ohlmann, M Stöckle, J Kamradt.   

Abstract

In Germany misteltoe extract is one of the most commonly used complementary therapeutic strategies in oncology. There are anthroposophical as well as phytotherapeutic concepts to explain the potential mechanism of action; however, the oncological and uro-oncological literature lacks definitive proof to support recommendations on which is the most effective drug, the optimal dose, a clear indication or its efficacy. Weighting the current data, potential side effects and contraindications, the application of mistletoe extract in daily uro-oncological practice requires careful consideration of the indications in the context of a detailed patient informed consent and request for this unique therapeutic modality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22996421     DOI: 10.1007/s00120-012-3006-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  10 in total

Review 1.  Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies.

Authors:  Gunver S Kienle; Helmut Kiene
Journal:  Integr Cancer Ther       Date:  2010-05-18       Impact factor: 3.279

Review 2.  The preclinical and clinical activity of aviscumine: a potential anticancer drug.

Authors:  Heinz Zwierzina; Lothar Bergmann; Heiner Fiebig; Steinar Aamdal; Patrick Schöffski; Klaus Witthohn; Hans Lentzen
Journal:  Eur J Cancer       Date:  2011-04-12       Impact factor: 9.162

3.  Characterization of recombinant and plant-derived mistletoe lectin and their B-chains.

Authors:  J Eck; M Langer; B Möckel; K Witthohn; H Zinke; H Lentzen
Journal:  Eur J Biochem       Date:  1999-10

4.  Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients.

Authors:  B M Heiny; J Beuth
Journal:  Anticancer Res       Date:  1994 May-Jun       Impact factor: 2.480

5.  Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer.

Authors:  Ursula Elsässer-Beile; Christian Leiber; Ulrich Wetterauer; Patrick Bühler; Philipp Wolf; Martin Lucht; Ulrich Mengs
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

6.  Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.

Authors:  P Schöffski; S Riggert; P Fumoleau; M Campone; O Bolte; S Marreaud; D Lacombe; B Baron; M Herold; H Zwierzina; K Wilhelm-Ogunbiyi; H Lentzen; C Twelves
Journal:  Ann Oncol       Date:  2004-12       Impact factor: 32.976

7.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

Review 8.  Mistletoe therapy in oncology.

Authors:  M A Horneber; G Bueschel; R Huber; K Linde; M Rostock
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

9.  Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial.

Authors:  Peter J Goebell; Thomas Otto; Julia Suhr; Herbert Rübben
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

10.  Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis.

Authors:  Arndt Büssing; Christa Raak; Thomas Ostermann
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-14       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.